Nanotechnology Now - Press Release: Nanoscope received NIH support for its first-in-class engineered mechanosensitive channel based gene therapy for glaucoma: Nanoscope received Direct Phase II SBIR grant from National Institutes of Health (NIH) for developing an innovative approach to autonomously regulate pressur

Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of chronic diseases, today announced that it has received $1.5 Million SBIR Direct-to-Phase II grant from NIH in support of its advancement of glaucoma therapy using Engineered Mechanosensitive Channel (EMC). The Nanoscope team has developed EMCs to sensitize cells toward abnormal mechanical stress related to pressure elevation caused by Glaucoma. SBIR Direct-to-Phase II grant award is based on demonstration of feasibility of the technology equivalent to meeting Phase I objectives and providing a solid foundation for the proposed Phase II activity.